Alan H Fairlamb

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/64133/publications.pdf

Version: 2024-02-01

272	24,758	11235	9605
papers	citations	73 h-index	147 g-index

287	287	287	18044
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 2002, 419, 498-511.	13.7	3,881
2	The Genome of the African Trypanosome Trypanosoma brucei. Science, 2005, 309, 416-422.	6.0	1,496
3	Drug Resistance in Leishmaniasis. Clinical Microbiology Reviews, 2006, 19, 111-126.	5.7	1,374
4	Metabolism and Functions of Trypanothione in the Kinetoplastida. Annual Review of Microbiology, 1992, 46, 695-729.	2.9	714
5	Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science, 1985, 227, 1485-1487.	6.0	657
6	Kinetoplastids: related protozoan pathogens, different diseases. Journal of Clinical Investigation, 2008, 118, 1301-1310.	3.9	460
7	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	13.7	353
8	Structure of trypanothione reductase from Crithidia fasciculata at 2.6 Ã... resolution; enzymeâ€“NADP interactions at 2.8 Ã... resolution. Acta Crystallographica Section D: Biological Crystallography, 1994, 50, 139-154.	2.5	343
9	Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature, 1993, 361, 173-176.	13.7	339
10	Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nature Reviews Microbiology, 2017, 15, 217-231.	13.6	315
11	Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Molecular Microbiology, 2002, 35, 542-552.	1.2	310
12	Chemotherapy of human African trypanosomiasis: current and future prospects. Trends in Parasitology, 2003, 19, 488-494.	1.5	292
13	Purification and characterization of trypanothione reductase from Crithidia fasciculata, a new member of the family of disulfide-containing flavoprotein reductases. Biochemistry, 1986, 25, 3519-3526.	1.2	282
14	Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO Journal, 1997, 16, 2590-2598.	3.5	272
15	N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.	13.7	272
16	Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania donovani. Journal of Biological Chemistry, 2004, 279, 39925-39932.	1.6	258
17	Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nature Immunology, 2003, 4, 485-490.	7.0	215
18	Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. Structure, 1999, 7, 81-89.	1.6	197

#	Article	IF	Citations
19	Uptake of Diamidine Drugs by the P2 Nucleoside Transporter in Melarsen-sensitive and -resistant Trypanosoma brucei brucei. Journal of Biological Chemistry, 1995, 270, 28153-28157.	1.6	185
20	Trypanothione is the primary target for arsenical drugs against African trypanosomes.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 2607-2611.	3.3	184
21	Trypanothione reductase from Trypanosoma cruzi. Purification and characterization of the crystalline enzyme. FEBS Journal, 1987, 164, 123-128.	0.2	173
22	Ovothiol and trypanothione as antioxidants in trypanosomatids. Molecular and Biochemical Parasitology, 2001, 115, 189-198.	0.5	171
23	In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Molecular and Biochemical Parasitology, 1987, 24, 185-191.	0.5	169
24	"Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 5374-5378.	3.3	169
25	Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: Effect on parasite intracellular survival. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 5311-5316.	3.3	167
26	Exploring the potential of xanthene derivatives as trypanothione reductase inhibitors and chloroquine potentiating agents. Tetrahedron, 2003, 59, 2289-2296.	1.0	161
27	Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. Biochemical Journal, 1992, 286, 9-11.	1.7	158
28	Evidence that trypanothione reductase is an essential enzyme inLeishmaniaby targeted replacement of thetryAgene locus. Molecular Microbiology, 1998, 29, 653-660.	1.2	154
29	The Structure of Reduced Tryparedoxin Peroxidase Reveals a Decamer and Insight into Reactivity of 2Cys-peroxiredoxins. Journal of Molecular Biology, 2000, 300, 903-916.	2.0	152
30	Phenothiazine Inhibitors of Trypanothione Reductase as Potential Antitrypanosomal and Antileishmanial Drugsâ€. Journal of Medicinal Chemistry, 1998, 41, 148-156.	2.9	148
31	Identification of a novel, thiol-containing co-factor essential for glutathione reductase enzyme activity in trypanosomatids. Molecular and Biochemical Parasitology, 1985, 14, 187-198.	0.5	141
32	Isolation and characterization of kinetoplast DNA from bloodstream form of Trypanosoma brucei.. Journal of Cell Biology, 1978, 76, 293-309.	2.3	140
33	Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay. Antimicrobial Agents and Chemotherapy, 2013, 57, 2913-2922.	1.4	135
34	The Biochemical Basis of Arsenicalâ€“Diamidine Crossresistance in African Trypanosomes. Parasitology Today, 1999, 15, 136-140.	3.1	134
35	Target assessment for antiparasitic drug discovery. Trends in Parasitology, 2007, 23, 589-595.	1.5	130
36	Active site of trypanothione reductase. Journal of Molecular Biology, 1992, 227, 322-333.	2.0	129

#	Article	IF	Citations
37	The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis. Science Translational Medicine, 2012, 4, 119re1.	5.8	126
38	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9318-9323.	3.3	119
39	Drug resistance in eukaryotic microorganisms. Nature Microbiology, 2016, 1, 16092.	5.9	118
40	Novel biochemical pathways in parasitic protozoa. Parasitology, 1989, 99, S93-S112.	0.7	116
41	Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis. Antimicrobial Agents and Chemotherapy, 2010, 54, 2893-2900.	1.4	112
42	Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature, 2018, 560, 192-197.	13.7	112
43	A Single Enzyme Catalyses Formation of Trypanothione from Glutathione and Spermidine in Trypanosoma cruzi. Journal of Biological Chemistry, 2002, 277, 35853-35861.	1.6	110
44	Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography. Journal of Medicinal Chemistry, 2011, 54, 6514-6530.	2.9	110
45	New approach to screening drugs for activity against African trypanosomes. Nature, 1977, 265, 270-271.	13.7	106
46	Trypanothione Reductase from Leishmania donovani. Purification, Characterisation and Inhibition by Trivalent Antimonials. FEBS Journal, 1995, 230, 460-468.	0.2	106
47	Identification and characterisation of a functional peroxidoxin from Leishmania major1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBankâ„¢ and DDJB databases under the accession number AF069386.1. Molecular and Biochemical Parasitology, 1998, 96, 125-137.	0.5	105
48	Cloning, expression and functional characterisation of a peroxiredoxin from the potato cyst nematode Globodera rostochiensis. Molecular and Biochemical Parasitology, 2000, 111, 41-49.	0.5	104
49	Substrate interactions between trypanothione reductase and N1-glutathionylspermidine disulphide at 0.28-nm resolution. FEBS Journal, 1993, 213, 67-75.	0.2	103
50	SURFACE RECEPTORS AND TRANSPORTERS OFTRYPANOSOMA BRUCEI. Annual Review of Microbiology, 1998, 52, 745-778.	2.9	102
51	Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 140-152.	2.9	102
52	Trypanothione dependent peroxide metabolism in Crithidia fasciculata and Trypanosoma brucei. Molecular and Biochemical Parasitology, 1987, 24, 39-45.	0.5	100
53	Target Validation: Linking Target and Chemical Properties to Desired Product Profile. Current Topics in Medicinal Chemistry, 2011, 11, 1275-1283.	1.0	99
54	Two Interacting Binding Sites for Quinacrine Derivatives in the Active Site of Trypanothione Reductase. Journal of Biological Chemistry, 2004, 279, 29493-29500.	1.6	97

#	Article	IF	Citations
55	Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo. Molecular and Biochemical Parasitology, 1980, 1, 315-333.	0.5	96
56	Substrate specificity of the flavoprotein trypanothione disulfide reductase from Crithidia fasciculata. Biochemistry, 1987, 26, 3023-3027.	1.2	96
57	One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 4454-4465.	2.9	96
58	Increased levels of thiols protect antimony unresponsiveLeishmania donovanifield isolates against reactive oxygen species generated by trivalent antimony. Parasitology, 2007, 134, 1679-1687.	0.7	94
59	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7015-7020.	3.3	94
60	Ornithine Decarboxylase Gene Deletion Mutants of Leishmania donovani. Journal of Biological Chemistry, 1999, 274, 3781-3788.	1.6	93
61	Melarsoprol Resistance in African Trypanosomiasis. Trends in Parasitology, 2018, 34, 481-492.	1.5	93
62	Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Biochemical Journal, 2003, 369, 529-537.	1.7	92
63	Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Molecular and Biochemical Parasitology, 1992, 53, 213-222.	0.5	91
64	The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 Ã... resolution. Protein Science, 1996, 5, 52-61.	3.1	89
65	A trypanothione-dependent glyoxalase I with a prokaryotic ancestry in Leishmania major. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13186-13191.	3.3	87
66	Leishmania Trypanothione Synthetase-Amidase Structure Reveals a Basis for Regulation of Conflicting Synthetic and Hydrolytic Activities. Journal of Biological Chemistry, 2008, 283, 17672-17680.	1.6	86
67	Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. FEBS Journal, 1994, 221, 285-295.	0.2	85
68	Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2655-2657.	1.0	85
69	Trypanothione biosynthesis in Leishmania major. Molecular and Biochemical Parasitology, 2005, 139, 107-116.	0.5	82
70	Carbohydrate Metabolism in African Trypanosomes, with Special Reference to the Glycosome. , 1986, , 183-224.		79
71	An improved technique for the cultivation of Plasmodium falciparum in vitro without daily medium change. Annals of Tropical Medicine and Parasitology, 1985, 79, 379-384.	1.6	77
72	A comparative study of methylglyoxal metabolism in trypanosomatids. FEBS Journal, 2009, 276, 376-386.	2.2	77

#	Article	IF	Citations
73	Specificity of the trypanothione-dependent Leishmania major glyoxalase I: structure and biochemical comparison with the human enzyme. Molecular Microbiology, 2006, 59, 1239-1248.	1.2	76
74	Molecular characterisation of mitochondrial and cytosolic trypanothione-dependent tryparedoxin peroxidases in Trypanosoma brucei. Molecular and Biochemical Parasitology, 2001, 116, 171-183.	0.5	75
75	Roles of Trypanothione S -Transferase and Tryparedoxin Peroxidase in Resistance to Antimonials. Antimicrobial Agents and Chemotherapy, 2008, 52, 1359-1365.	1.4	73
76	Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania. PLoS Pathogens, 2016, 12, e1005971.	2.1	73
77	Identification and Biosynthesis of N1,N9-Bis(Glutathionyl)Aminopropylcadaverine (Homotrypanothione) in Trypanosoma Cruzi. FEBS Journal, 1994, 226, 1019-1027.	0.2	72
78	Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. Biochemical Journal, 2006, 393, 447-457.	1.7	72
79	Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line. Biochemical Pharmacology, 2006, 71, 257-267.	2.0	72
80	Diamine auxotrophy may be a universal feature of Trypanosoma cruzi epimastigotes. Molecular and Biochemical Parasitology, 1997, 84, 111-121.	0.5	71
81	Dissecting the essentiality of the bifunctional trypanothione synthetaseâ€amidase in Trypanosoma brucei using chemical and genetic methods. Molecular Microbiology, 2009, 74, 529-540.	1.2	71
82	Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase. Sensitivity towards agents that are thought to induce oxidative stress. FEBS Journal, 1993, 218, 29-37.	0.2	69
83	Phenotypic analysis of trypanothione synthetase knockdown in the African trypanosome. Biochemical Journal, 2005, 391, 425-432.	1.7	69
84	Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Molecular and Biochemical Parasitology, 2010, 173, 162-164.	0.5	69
85	Identification of a Î¹-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochemical Pharmacology, 2010, 80, 1478-1486.	2.0	69
86	Chemical Validation of Trypanothione Synthetase. Journal of Biological Chemistry, 2009, 284, 36137-36145.	1.6	68
87	Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity. Antimicrobial Agents and Chemotherapy, 2009, 53, 2824-2833.	1.4	67
88	The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. ELife, 2016, 5, .	2.8	67
89	Purification of glutathionylspermidine and trypanothione synthetases from crithidia fasciculata. Protein Science, 1992, 1, 874-883.	3.1	66
90	Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 9672-9685.	2.9	66

#	Article	IF	Citations
91	Regulation of a high-affinity diamine transport system in Trypanosoma cruzi epimastigotes. Biochemical Journal, 1996, 316, 481-486.	1.7	65
92	Norspermidine Is Not a Self-Produced Trigger for Biofilm Disassembly. Cell, 2014, 156, 844-854.	13.5	65
93	Nitroheterocyclic drug resistance mechanisms inTrypanosoma brucei. Journal of Antimicrobial Chemotherapy, 2016, 71, 625-634.	1.3	65
94	Biochemical changes associated with Î±-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Molecular and Biochemical Parasitology, 1987, 25, 227-238.	0.5	64
95	Characterization of protein Ser/Thr phosphatases of the malaria parasite, Plasmodium falciparum: inhibition of the parasitic calcineurin by cyclophilin-cyclosporin complex. Molecular and Biochemical Parasitology, 1999, 99, 167-181.	0.5	64
96	A new expression vector for Crithidia fasciculata and Leishmania. Molecular and Biochemical Parasitology, 2002, 120, 195-204.	0.5	63
97	Chemical and genetic validation of dihydrofolate reductaseâ€“thymidylate synthase as a drug target in African trypanosomes. Molecular Microbiology, 2008, 69, 520-533.	1.2	63
98	Improved Tricyclic Inhibitors of Trypanothione Reductase by Screening and Chemical Synthesis. ChemMedChem, 2009, 4, 1333-1340.	1.6	63
99	Site-Directed Mutagenesis of the Redox-Active Cysteines of Trypanosoma cruzi Trypanothione Reductase. FEBS Journal, 1995, 228, 745-752.	0.2	63
100	The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2013, 57, 4699-4706.	1.4	62
101	The High Resolution Crystal Structure of Recombinant Crithidia fasciculata Tryparedoxin-I. Journal of Biological Chemistry, 1999, 274, 25613-25622.	1.6	61
102	The biosynthesis of trypanothione and N1-glutathionylspermidine in Crithidia fasciculata. Molecular and Biochemical Parasitology, 1986, 21, 247-257.	0.5	59
103	Bimane cyclic esters, possible stereologues of trypanothione as antitrypanosomal agents. Bimanes 29. European Journal of Medicinal Chemistry, 1995, 30, 659-671.	2.6	59
104	Properties of trypanothione synthetase from Trypanosoma brucei. Molecular and Biochemical Parasitology, 2003, 131, 25-33.	0.5	57
105	Bis(glutathionyl)spermine and Other Novel Trypanothione Analogues in Trypanosoma cruzi. Journal of Biological Chemistry, 2003, 278, 27612-27619.	1.6	57
106	Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate. Molecular Microbiology, 2006, 61, 1457-1468.	1.2	57
107	Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 9855-9869.	2.9	57
108	Trypanothione S-Transferase Activity in a Trypanosomatid Ribosomal Elongation Factor 1B. Journal of Biological Chemistry, 2004, 279, 27246-27256.	1.6	56

#	Article	IF	Citations
109	Anti-plasmodial and anti-trypanosomal activity of synthetic naphtho[2,3-b]thiophen-4,9-quinones. Bioorganic and Medicinal Chemistry, 1997, 5, 2185-2192.	1.4	55
110	Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani. ACS Infectious Diseases, 2019, 5, 111-122.	1.8	55
111	Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei. ChemMedChem, 2009, 4, 2060-2069.	1.6	54
112	Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi. Molecular and Biochemical Parasitology, 2010, 169, 12-19.	0.5	54
113	Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19932-19937.	3.3	54
114	Leishmania major Elongation Factor 1B Complex Has Trypanothione S-Transferase and Peroxidase Activity. Journal of Biological Chemistry, 2004, 279, 49003-49009.	1.6	53
115	Lipoprotein lipase suppression in 3T3â€Ł1 cells by a haematoprotozoanâ€induced mediator from peritoneal exudate cells. Parasite Immunology, 1984, 6, 203-209.	0.7	52
116	Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Molecular and Biochemical Parasitology, 1995, 69, 289-298.	0.5	51
117	Cloning, expression and reconstitution of the trypanothione-dependent peroxidase system of Crithidia fasciculata1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBank and DDJB databases under the GenBank accession numbers AF055913 (tryparedoxin) and AF055914 (tryparedoxin peroxidase).1. Molecular and Biochemical Parasitology, 1998, 96, 111-123.	0.5	51
118	Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione Reductase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 1670-1680.	2.9	50
119	Assessing the Essentiality of Leishmania donovani Nitroreductase and Its Role in Nitro Drug Activation. Antimicrobial Agents and Chemotherapy, 2013, 57, 901-906.	1.4	50
120	Trypanosoma brucei: Suramin and other trypanocidal compounds' effects on sn-glycerol-3-phosphate oxidase. Experimental Parasitology, 1977, 43, 353-361.	0.5	49
121	Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1422-1427.	1.0	49
122	Synthesis of N-benzyloxycarbonyl-l-cysteinylglycine 3-dimethylaminopropylamide disulfide: A cheap and convenient new assay for trypanothione reductase. Analytical Biochemistry, 1991, 198, 212-216.	1.1	48
123	Molecular characterization of the trypanothione reductase gene from Crithidia fasciculata and Trypanosoma brucei: comparison with other flavoprotein disulphide oxidoreductases with respect to substrate specificity and catalytic machanism. Molecular Microbiology, 1992, 6, 3089-3099.	1.2	48
124	Characterization of recombinant glutathionylspermidine synthetase/amidase from Crithidia fasciculata. Biochemical Journal, 2002, 364, 679-686.	1.7	48
125	Trypanothione-dependent glyoxalase I in Trypanosoma cruzi. Biochemical Journal, 2006, 400, 217-223.	1.7	48
126	Dissecting the Metabolic Roles of Pteridine Reductase 1 in Trypanosoma brucei and Leishmania major. Journal of Biological Chemistry, 2011, 286, 10429-10438.	1.6	47

#	Article	IF	Citations
127	Future prospects for the chemotherapy of human trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 613-617.	0.7	46
128	Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice. Molecular Microbiology, 2010, 77, 658-671.	1.2	46
129	Methylglyoxal metabolism in trypanosomes and leishmania. Seminars in Cell and Developmental Biology, 2011, 22, 271-277.	2.3	46
130	An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 811-816.	1.0	45
131	Synthesis and Evaluation of 1â€(1â€(Benzo[b]thiophenâ€2â€yl)cyclohexyl)piperidine (BTCP) Analogues as Inhibitors of Trypanothione Reductase. ChemMedChem, 2009, 4, 1341-1353.	1.6	45
132	Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?. PLoS Neglected Tropical Diseases, 2011, 5, e1227.	1.3	45
133	Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase. ACS Infectious Diseases, 2017, 3, 34-44.	1.8	45
134	Detailed characterization of a cyclophilin from the human malaria parasite Plasmodium falciparum. Biochemical Journal, 1998, 334, 437-445.	1.7	44
135	Allosteric Activation of Trypanosomatid Deoxyhypusine Synthase by a Catalytically Dead Paralog. Journal of Biological Chemistry, 2013, 288, 15256-15267.	1.6	44
136	Tryparedoxins from Crithidia fasciculata and Trypanosoma brucei. Journal of Biological Chemistry, 2003, 278, 25919-25925.	1.6	43
137	Biosynthesis of the trypanosomatid metabolite trypanothione: purification and characterization of trypanothione synthetase from Crithidia fasciculata. Biochemistry, 1990, 29, 3924-3929.	1.2	42
138	MYST Family Histone Acetyltransferases in the Protozoan Parasite Toxoplasma gondii. Eukaryotic Cell, 2005, 4, 2057-2065.	3.4	42
139	Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors. ChemMedChem, 2012, 7, 95-106.	1.6	42
140	Glutathionylspermidine metabolism in Escherichia coli. Biochemical Journal, 1995, 312, 465-469.	1.7	41
141	Trypanosoma Cruzitrypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radical Research, 2001, 34, 363-378.	1.5	41
142	Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis. Current Medicinal Chemistry, 2019, 26, 4454-4475.	1.2	41
143	Biochemistry of trypanosomiasis and rational approaches to chemotherapy. Trends in Biochemical Sciences, 1982, 7, 249-253.	3.7	40
144	Trypanothione metabolism: a chemotherapeutic target in trypanosomatids. Parasitology Today, 1987, 3, 312-315.	3.1	40

#	Article	IF	Citations
145	Subcellular distribution of trypanothione reductase in bloodstream and procyclic forms of Trypanosoma brucei. Molecular and Biochemical Parasitology, 1991, 48, 109-112.	0.5	40
146	Cloning and Characterization of the Two Enzymes Responsible for Trypanothione Biosynthesis in Crithidia fasciculata. Journal of Biological Chemistry, 1998, 273, 19383-19390.	1.6	40
147	High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1280-1283.	1.0	40
148	Phosphonic acid and phosphinic acid tripeptides as inhibitors of glutathionylspermidine synthetase. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 253-258.	1.0	39
149	The three-dimensional structure of a Plasmodium falciparum cyclophilin in complex with the potent anti-malarial cyclosporin A. Journal of Molecular Biology, 2000, 298, 123-133.	2.0	39
150	Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductaseâ€...1. ChemMedChem, 2011, 6, 302-308.	1.6	39
151	The structure, organization, and expression of the Leishmania donovani gene encoding trypanothione reductase. Molecular and Biochemical Parasitology, 1994, 64, 293-301.	0.5	38
152	The isolation and characterisation of particulate sn-glycerol-3-phosphate oxidase from Trypanosoma brucei. International Journal of Biochemistry & Cell Biology, 1977, 8, 659-668.	0.8	37
153	Arsenic Exposure and Outcomes of Antimonial Treatment in Visceral Leishmaniasis Patients in Bihar, India: A Retrospective Cohort Study. PLoS Neglected Tropical Diseases, 2015, 9, e0003518.	1.3	37
154	Rational design of selective ligands for trypanothione reductase fromtrypanosoma cruzStructural effects on the inhibition by dibenzazepines based on imipramine. Journal of Enzyme Inhibition and Medicinal Chemistry, 1997, 12, 161-173.	0.5	35
155	A comparative study of typeâ€ƒI and typeâ€ƒII tryparedoxin peroxidases in Leishmania major. FEBS Journal, 2007, 274, 5643-5658.	2.2	35
156	TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei. Nucleic Acids Research, 2015, 43, D637-D644.	6.5	35
157	Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome. PLoS Neglected Tropical Diseases, 2015, 9, e0004299.	1.3	34
158	Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases. Parasitology, 1992, 105, S71-S78.	0.7	33
159	The interaction of arsenical drugs with dihydrolipoamide and dihydrolipoamide dehydrogenase from arsenical resistant and sensitive strains of Trypanosoma brucei brucei. Molecular and Biochemical Parasitology, 1992, 53, 223-231.	0.5	33
160	Time-dependent inhibitors of trypanothione reductase: Analogues of the spermidine alkaloid lunarine and related natural products. Bioorganic and Medicinal Chemistry, 2006, 14, 2266-2278.	1.4	31
161	Antitumor Quinol PMX464 Is a Cytocidal Anti-trypanosomal Inhibitor Targeting Trypanothione Metabolism. Journal of Biological Chemistry, 2011, 286, 8523-8533.	1.6	31
162	Nongenotoxic 3-Nitroimidazo[1,2-a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity. ACS Medicinal Chemistry Letters, 2019, 10, 34-39.	1.3	31

#	Article	IF	Citations
163	Transport of ethanolamine and its incorporation into the variant surface glycoprotein of bloodstream forms of Trypanosoma brucei. Molecular and Biochemical Parasitology, 1985, 15, 245-256.	0.5	30
164	A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery Programmes. PLoS Neglected Tropical Diseases, 2012, 6, e1932.	1.3	30
165	Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome. Molecular Microbiology, 2012, 86, 51-64.	1.2	30
166	Trypanosoma brucei: Maintenance of concentrated suspensions of bloodstream trypomastigotes in vitro using continuous dialysis for measurement of endocytosis. Experimental Parasitology, 1980, 49, 366-380.	0.5	29
167	Properties of melarsamine hydrochloride (Cymelarsan) in aqueous solution. Antimicrobial Agents and Chemotherapy, 1994, 38, 1298-1302.	1.4	29
168	Entamoeba histolytica lacks trypanothione metabolism. Molecular and Biochemical Parasitology, 1999, 103, 61-69.	0.5	29
169	Inhibitor studies on particulate sn-glycerol-3-phosphate oxidase from Trypanosoma brucei. International Journal of Biochemistry & Cell Biology, 1977, 8, 669-675.	0.8	28
170	Specificity of Ethanolamine Transport and Its Further Metabolism in Trypanosoma brucei. Journal of Biological Chemistry, 1995, 270, 16160-16166.	1.6	28
171	Biochemical and genetic characterization ofTrypanosoma cruzi N-myristoyltransferase. Biochemical Journal, 2014, 459, 323-332.	1.7	28
172	Trypanothione metabolism and rational approaches to drug design. Biochemical Society Transactions, 1990, 18, 717-720.	1.6	27
173	Activity of disulfiram (bis(diethylthiocarbamoyl)disulphide) and ditiocarb (diethyldithiocarbamate) against metronidazole-sensitive and - resistant Trichomonas vaginalis and Tritrichomonas foetus [In Process Citation]. Journal of Antimicrobial Chemotherapy, 1998, 42, 817-820.	1.3	27
174	Uptake of the nitroimidazole drug megazol by African trypanosomes. Biochemical Pharmacology, 2000, 59, 615-620.	2.0	27
175	Benzofuranyl 3,5-bis-Polyamine derivatives as time-Dependent inhibitors of trypanothione reductase. Bioorganic and Medicinal Chemistry, 2003, 11, 3683-3693.	1.4	27
176	Polyamine and pentamidine metabolism in African trypanosomes. Acta Tropica, 1993, 54, 215-224.	0.9	26
177	Extrachromosomal, homologous expression of trypanothione reductase and its complementary mRNA in Trypanosoma cruzi. Nucleic Acids Research, 1996, 24, 2942-2949.	6.5	26
178	Bis-Acridines as Lead Antiparasitic Agents: Structure-Activity Analysis of a Discrete Compound Library In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 2164-2172.	1.4	26
179	Metabolic pathway analysis in trypanosomes and malaria parasites. Philosophical Transactions of the Royal Society B: Biological Sciences, 2002, 357, 101-107.	1.8	25
180	ATPâ€dependent ligases in trypanothione biosynthesis â€“ kinetics of catalysis and inhibition by phosphinic acid pseudopeptides. FEBS Journal, 2008, 275, 5408-5421.	2.2	25

#	Article	IF	Citations
181	Characterization of kinetoplast DNA networks from the insect trypanosome Crithidia luciliae. Nucleic Acids and Protein Synthesis, 1977, 478, 167-179.	1.7	24
182	Synthesis of the trypanosomatid metabolites trypanothione, and N 1-mono- and N 8-mono-glutathionylspermidine. Journal of the Chemical Society Chemical Communications, 1986, , 593.	2.0	24
183	Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 1: Substitution of the glycine carboxylic acid group. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2553-2556.	1.0	24
184	Structural and mechanistic insights into typeÂII trypanosomatid tryparedoxin-dependent peroxidases. Biochemical Journal, 2008, 414, 375-381.	1.7	24
185	Rational design of peptide-based inhibitors of trypanothione reductase as potential antitrypanosomal drugs. Amino Acids, 1994, 6, 295-299.	1.2	23
186	Development and validation of a cytochrome c-coupled assay for pteridine reductase 1 and dihydrofolate reductase. Analytical Biochemistry, 2010, 396, 194-203.	1.1	23
187	The Q_i Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani. ACS Infectious Diseases, 2020, 6, 515-528.	1.8	23
188	Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase. PLoS Neglected Tropical Diseases, 2016, 10, e0004714.	1.3	23
189	Initiating a crystallographic study of trypanothione reductase. Journal of Molecular Biology, 1990, 216, 235-237.	2.0	22
190	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani. ACS Infectious Diseases, 2017, 3, 718-727.	1.8	22
191	A simple magnetic method for the purification of malarial pigment. Molecular and Biochemical Parasitology, 1984, 12, 307-312.	0.5	21
192	Trypanothione Reductase from Leishmania donovani. Purification, Characterisation and Inhibition by Trivalent Antimonials. FEBS Journal, 1995, 230, 460-468.	0.2	21
193	Refinement of techniques for the propagation of Leishmania donovani in hamsters. Acta Tropica, 2006, 97, 364-369.	0.9	21
194	<scp>T</scp>rypanosoma brucei (<scp>UMP</scp> synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy. Molecular Microbiology, 2013, 90, 443-455.	1.2	21
195	Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment- resistant kala-azar?. Lancet, The, 2015, 385, S80.	6.3	21
196	The Role of Folate Transport in Antifolate Drug Action in Trypanosoma brucei. Journal of Biological Chemistry, 2016, 291, 24768-24778.	1.6	21
197	Molecular characterization and expression of Onchocerca volvulus glutathione reductase. Biochemical Journal, 1997, 325, 645-651.	1.7	20
198	Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei , Trypanosoma cruzi and Leishmania donovani. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1147-1150.	1.0	20

#	Article	IF	Citations
199	Regiocontrolled synthesis of the macrocyclic polyamine alkaloid (Â±)-lunarine, a time-dependent inhibitor of trypanothione reductase. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 1115-1123.	1.3	20
200	The N-myristoylome of Trypanosoma cruzi. Scientific Reports, 2016, 6, 31078.	1.6	20
201	Differential susceptibility of filarial and human erythrocyte glutathione reductase to inhibition by the trivalent organic arsenical melarsen oxide. Molecular and Biochemical Parasitology, 1995, 71, 211-219.	0.5	19
202	Characterization of the peptide substrate specificity of glutathionylspermidine synthetase from Crithidia fasciculata. Molecular and Biochemical Parasitology, 1997, 84, 25-32.	0.5	19
203	Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: Substitution of the glycine part. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2703-2705.	1.0	19
204	Properties of Phosphoenolpyruvate Mutase, the First Enzyme in the Aminoethylphosphonate Biosynthetic Pathway in Trypanosoma cruzi. Journal of Biological Chemistry, 2003, 278, 22703-22708.	1.6	19
205	Synthesis and Evaluation of Indatralineâ€Based Inhibitors for Trypanothione Reductase. ChemMedChem, 2011, 6, 321-328.	1.6	19
206	8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases. European Journal of Medicinal Chemistry, 2018, 157, 115-126.	2.6	19
207	Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study. European Journal of Medicinal Chemistry, 2018, 155, 135-152.	2.6	19
208	Peptoid inhibition of trypanothione reductase as a potential antitrypanosomal and antileishmanial drug lead. Amino Acids, 2002, 22, 297-308.	1.2	18
209	Homoserine and quorumâ€sensing acyl homoserine lactones as alternative sources of threonine: a potential role for homoserine kinase in insectâ€stage Trypanosoma brucei. Molecular Microbiology, 2015, 95, 143-156.	1.2	18
210	Fexinidazole for the treatment of human African trypanosomiasis. Drugs of Today, 2019, 55, 705.	0.7	18
211	Triclosan is minimally effective in rodent malaria models. Nature Medicine, 2011, 17, 33-34.	15.2	17
212	Quinol derivatives as potential trypanocidal agents. Bioorganic and Medicinal Chemistry, 2012, 20, 1607-1615.	1.4	17
213	Enzymatic Inhibitory Activity and Trypanocidal Effects of Extracts and Compounds from Siphoneugena densiflora O. Berg and Vitex polygama Cham.. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2008, 63, 371-382.	0.6	16
214	Inhibition of polyamine biosynthesis in Crithidia fasciculata by d,l-Î±-difluoromethylornithine and d,l-Î±-difluoromethylarginine. Molecular and Biochemical Parasitology, 1991, 46, 35-43.	0.5	15
215	Specific peptide inhibitors of trypanothione reductase with backbone structures unrelated to that of substrate: potential rational drug design lead frameworks. Amino Acids, 2001, 20, 145-153.	1.2	15
216	Very Short and Efficient Syntheses of the Spermine Alkaloid Kukoamine A and Analogs Using Isolable Succinimidyl Cinnamates. Chemistry Letters, 2005, 34, 264-265.	0.7	15

#	Article	IF	Citations
217	8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T.Âb. brucei and cruzi. European Journal of Medicinal Chemistry, 2020, 202, 112558.	2.6	15
218	Cloning of a pyruvate phosphate dikinase from Trypanosoma cruzi. Molecular and Biochemical Parasitology, 2001, 112, 183-191.	0.5	14
219	Computer assisted design of potentially active anti-trypanosomal compounds. Computational and Theoretical Chemistry, 2002, 584, 95-105.	1.5	14
220	8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Memorias Do Instituto Oswaldo Cruz, 2003, 98, 565-568.	0.8	14
221	Synthesis, biological profiling and mechanistic studies of 4-aminoquinoline-based heterodimeric compounds with dual trypanocidalâ€“antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2015, 23, 5156-5167.	1.4	14
222	Site-Directed Mutagenesis of the Redox-Active Cysteines of Trypanosoma cruzi Trypanothione Reductase. FEBS Journal, 1995, 228, 745-752.	0.2	13
223	Macrocyclic polyamine lactam synthesis by diphenyl ether closure of 23-, 24- and 28-membered rings. Chemical Communications, 1998, , 2335-2336.	2.2	13
224	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. Journal of Medicinal Chemistry, 2016, 59, 6101-6120.	2.9	13
225	Screening a protein kinase inhibitor library against Plasmodium falciparum. Malaria Journal, 2017, 16, 446.	0.8	12
226	Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
227	A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism. Biochemical Journal, 2018, 475, 2593-2610.	1.7	12
228	Cytochrome P450 in trypanosomatids. Biochemical Pharmacology, 1993, 46, 149-157.	2.0	11
229	Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T.Âb. brucei hit-compound with improved pharmacokinetic properties. European Journal of Medicinal Chemistry, 2020, 206, 112668.	2.6	11
230	Discovery of an Allosteric Binding Site in Kinetoplastid Methionyl-tRNA Synthetase. ACS Infectious Diseases, 2020, 6, 1044-1057.	1.8	11
231	Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial. Cell Chemical Biology, 2021, 28, 711-721.e8.	2.5	11
232	The glutamyl binding site of trypanothione reductase from Crithidia fasciculata: enzyme kinetic properties of Î³-glutamyl-modified substrate analogues. BBA - Proteins and Proteomics, 1993, 1203, 93-98.	2.1	10
233	Trypanosoma cruzi Trypanothione Reductase Crystallization, Unit Cell Dimensions and Structure Solution. Journal of Molecular Biology, 1993, 232, 1217-1220.	2.0	10
234	Crystallization and preliminary X-ray analysis ofLeishmania majorglyoxalase I. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 769-772.	0.7	10

#	Article	IF	Citations
235	Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases. Nature Reviews Drug Discovery, 2016, 15, 292-292.	21.5	10
236	Synthesis and antitrypanosomal evaluation of some thiazole-containing amino acids and peptides. European Journal of Medicinal Chemistry, 1993, 28, 387-397.	2.6	9
237	Genomics decodes drug action. Nature, 2012, 482, 167-169.	13.7	9
238	Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity. ACS Medicinal Chemistry Letters, 2021, 12, 1405-1412.	1.3	9
239	Mapping the functional synthetase domain of trypanothione synthetase from Leishmania major. Molecular and Biochemical Parasitology, 2006, 149, 117-120.	0.5	8
240	Antitrypanosomatid Pharmacomodulation at Position 3 of the 8â€Nitroquinolinâ€2(1H)â€one Scaffold Using Palladiumâ€Catalysed Crossâ€Coupling Reactions. ChemMedChem, 2018, 13, 2217-2228.	1.6	8
241	Characterisation of a putative glutamate 5â€kinase from Leishmania donovani. FEBS Journal, 2018, 285, 2662-2678.	2.2	8
242	New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi. ACS Medicinal Chemistry Letters, 2020, 11, 464-472.	1.3	8
243	Chloroquine Resistance Is Not Associated with Drug Metabolism in Plasmodium falciparum. Journal of Parasitology, 1995, 81, 1004.	0.3	7
244	Optimisation of the Antiâ€Trypanosoma brucei Activity of the Opioid Agonist U50488. ChemMedChem, 2011, 6, 1832-1840.	1.6	7
245	Inhibition of trypanothione reductase and glutathione reductase by ferrocenic 4-aminoquinoline ureas. Arkivoc, 2008, 2008, 52-60.	0.3	7
246	The interaction of trypanocidal drugs with polyamine and trypanothione metabolism. Biochemical Society Transactions, 1990, 18, 1094-1096.	1.6	6
247	Purification of glutathione reductase from muscle of the adult parasitic nematode Ascaris suum. Molecular and Biochemical Parasitology, 1992, 51, 331-333.	0.5	6
248	Inhibition of Leishmania Species by Î±-Difluoromethylornithine. , 1989, , 749-756.		6
249	The trypanothione reductase gene of Leishmania donovani. Biochemical Society Transactions, 1990, 18, 869-870.	1.6	5
250	Separation and quantitation of the polyamine biosynthesis inhibitor d,l-Î±-difluoromethylarginine and other guanidine-containing compounds by high-performance liquid chromatography. Analytical Biochemistry, 1990, 190, 281-285.	1.1	5
251	High-performance liquid chromatographic method for the separation and quantitative estimation of anti-parasitic melaminophenyl arsenical compounds. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 357-359.	0.7	5
252	The Determination of Polyamines and Amino Acids by a Fluorescamine-HPLC Method. , 1998, 79, 125-130.		5

#	Article	IF	Citations
253	Crystallization of RecombinantCrithidia fasciculataTryparedoxin. Journal of Structural Biology, 1999, 126, 76-79.	1.3	5
254	Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes. Journal of Antimicrobial Chemotherapy, 2016, 71, 956-963.	1.3	5
255	Substituted Aminoacetamides as Novel Leads for Malaria Treatment. ChemMedChem, 2019, 14, 1329-1335.	1.6	5
256	An improved method for the estimation of suramin in plasma and trypanosome samples. Molecular and Biochemical Parasitology, 1980, 1, 307-313.	0.5	4
257	Fluphenazine photoaffinity labelling of binding sites for phenothiazine inhibitors of trypanothione reductase. Chemical Communications, 1996, , 973.	2.2	4
258	Diamine auxotrophy in a eukaryotic parasite. Biochemical Society Transactions, 1998, 26, 606-609.	1.6	4
259	Synthesis and enzymology of modifiedN-benzyloxycarbonyl-L-cysteinylglycyl-3,3-dimethylaminopropylamide disulphides as alternative substrates for trypanothione reductase fromTrypanosoma crud: Part 3. Amino Acids, 1999, 17, 175-183.	1.2	4
260	The Role of Glutathionylspermidine and Trypanothione in Regulation of Intracellular Spermidine Levels During Growth of Crithidia Fasciculata. Advances in Experimental Medicine and Biology, 1988, 250, 667-674.	0.8	4
261	Measurement of Polyamine Transport: Cells in Suspension. , 1998, 79, 149-156.		3
262	Inhibitors of trypanothione reductase as potential antitrypanosomal drugs. Biochemical Society Transactions, 1995, 23, 511S-511S.	1.6	2
263	Renewed Strategies for Drug Development against Parasitic Diseases. Parasitology Today, 1999, 15, 393-394.	3.1	2
264	Antimicrobial drug discovery. Future Microbiology, 2011, 6, 601-602.	1.0	2
265	Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases. Nature Reviews Drug Discovery, 2021, 20, 799-800.	21.5	2
266	Metabolism and Functions of Trypanothione with Special Reference to Leishmaniasis. , 1989, , 487-494.		2
267	Erratum for De Rycker et al., Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay. Antimicrobial Agents and Chemotherapy, 2014, 58, 7622-7622.	1.4	1
268	Development of Chemical Proteomics for the Folateome and Analysis of the Kinetoplastid Folateome. ACS Infectious Diseases, 2018, 4, 1475-1486.	1.8	1
269	Surmounting structural barriers to tackle endemic infectious diseases. Journal of Experimental Medicine, 2021, 218, .	4.2	1
270	Assessment of the polyamine metabolism of filarial worms as a target for chemotherapy. Parasite, 1994, 1, S60-S61.	0.8	0

#	Article	IF	Citations
271	FC4 glutathionylspermidine synthethase from Crithidia fasciculata: Kinetic properties of glutathione and spermidine analogues. European Journal of Pharmaceutical Sciences, 1994, 2, 101.	1.9	0
272	p-(4,6-Diamino-s-triazin-2-yl)aminophenylarsonic Acid Dihydrate. Acta Crystallographica Section C: Crystal Structure Communications, 1995, 51, 1953-1955.	0.4	0